
Claims:

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

X is CH, CR^2, or N;

R^1 is (C_1-C_4)alkyl, (C_3-C_7)cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, or 5- or 6-membered heteroaryl, wherein said (C_1-C_4)alkyl is optionally substituted by hydroxyl, (C_1-C_4)alkoxy, -CO_2H, or -CO_2(C_1-C_4)alkyl, and wherein said phenyl or 5- or 6-membered heteroaryl is optionally substituted by -O(C_1-C_2)alkylO- or optionally substituted with one to three substituents independently selected from halogen, cyano, oxo, hydroxyl, (C_1-C_4)alkoxy, halo(C_1-C_4)alkoxy, (C_3-C_7)cycloalkoxy, phenyl(C_1-C_2)alkoxy, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, hydroxy(C_1-C_4)alkyl, -CO_2H, and -CO_2(C_1-C_4)alkyl; and

R^2 is halogen, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, (C_3-C_7)cycloalkyl, 4- to 6-membered heterocycloalkyl, -NHC(O)(C_1-C_4)alkyl, or -NHC(O)(C_3-C_7)cycloalkyl;

provided that the compound is not 4-amino-6-(1-propyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-cyclopropyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 3-(5-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-6(5*H*)-yl)-1*H*-indol-1-yl)propanoic acid, 4-amino-6-(1-(3-methoxypropyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-methyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-methoxyethyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-isopropyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-propyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-methoxyethyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-cyclohexyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-isopropyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-hydroxyethyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-cyclopropyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-phenyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-

amino-6-(1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-chlorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-chlorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 6-amino-4-(7-(2-methoxyphenyl)-7*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-3,4-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(2*H*)-one, 4-amino-6-(1-(2-methoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-phenyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3,4-difluorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3,4-difluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-fluorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-(trifluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-(trifluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-(trifluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(thiazol-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(6-(trifluoromethyl)pyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyridin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyridin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyrazin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyrazin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(5-(trifluoromethyl)pyridin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(5-(trifluoromethyl)pyridin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(thiazol-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(6-(trifluoromethyl)pyridin-3-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(6-methylpyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-(difluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-(difluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, or 4-amino-6-(1-(4-(trifluoromethyl)pyridin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one.

2. The compound or pharmaceutically acceptable salt according to claim 1 wherein X is CH or CR^2.

3. The compound or pharmaceutically acceptable salt according to claim 1 wherein X is CH.

4. The compound or pharmaceutically acceptable salt according to claim 1 wherein X is N.

5. The compound or pharmaceutically acceptable salt according to claim 1 or claim 2 wherein R^2 is $(C_3$-$C_7)$cycloalkyl, 4- to 6-membered heterocycloalkyl, or -NHC(O)$(C_3$-$C_7)$cycloalkyl.

6. The compound or pharmaceutically acceptable salt according to claim 5 wherein R^2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, -NHC(O)cyclopropyl, -NHC(O)cyclobutyl, -NHC(O)cyclopentyl, or -NHC(O)cyclohexyl.

7. The compound or pharmaceutically acceptable salt according to any one of claims 1-6 wherein R^1 is $(C_1$-$C_4)$alkyl which is optionally substituted by hydroxyl, $(C_1$-$C_4)$alkoxy, $-CO_2H$, or $-CO_2(C_1$-$C_4)$alkyl.

8. The compound or pharmaceutically acceptable salt according to any one of claims 1-6 wherein R^1 is $(C_3$-$C_7)$cycloalkyl or 4- to 6-membered heterocycloalkyl.

9. The compound or pharmaceutically acceptable salt according to claim 8 wherein R^1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, or tetrahydropyranyl.

10. The compound or pharmaceutically acceptable salt according to any one of claims 1-6 wherein R^1 is phenyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, or triazinyl, each of which is optionally substituted by -O$(C_1$-$C_2)$alkylO- or optionally substituted with one to three substituents independently selected from halogen, cyano, oxo, hydroxyl, $(C_1$-$C_4)$alkoxy, halo$(C_1$-$C_4)$alkoxy, $(C_3$-$C_7)$cycloalkoxy, phenyl$(C_1$-$C_2)$alkoxy, $(C_1$-$C_4)$alkyl, halo$(C_1$-$C_4)$alkyl, hydroxy$(C_1$-$C_4)$alkyl, $-CO_2H$, and $-CO_2(C_1$-$C_4)$alkyl.

11. The compound or pharmaceutically acceptable salt according to claim 10 wherein R^1 is phenyl which is optionally substituted by -O(C_1-C_2)alkylO- or optionally substituted with one or two substituents independently selected from fluorine, chlorine, hydroxyl, (C_1-C_4)alkoxy, halo(C_1-C_4)alkoxy, (C_3-C_7)cycloalkoxy, (C_1-C_4)alkyl, and halo(C_1-C_4)alkyl.

12. The compound or pharmaceutically acceptable salt according to claim 10 wherein R^1 is furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, or isothiazolyl, each of which is optionally substituted with one or two substituents independently selected from hydroxyl, (C_1-C_4)alkoxy, halo(C_1-C_4)alkoxy, (C_3-C_7)cycloalkoxy, (C_1-C_4)alkyl, and halo(C_1-C_4)alkyl.

13. The compound or pharmaceutically acceptable salt according to claim 10 wherein R^1 is pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl, each of which is optionally substituted with one or two substituents independently selected from oxo, hydroxyl, (C_1-C_4)alkoxy, halo(C_1-C_4)alkoxy, (C_3-C_7)cycloalkoxy, (C_1-C_4)alkyl, and halo(C_1-C_4)alkyl.

14. The compound according to claim 1 which is:

4-amino-6-(1-(oxetan-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-(trifluoromethoxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-cyclobutyl-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-hydroxy-2-methylpropyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-(trifluoromethoxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-4-(trifluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-(difluoromethoxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-isobutoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-isopropoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3,5-dichlorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3,5-dichlorophenyl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2,3-dichlorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methylpyrimidin-5-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(6-methylpyridin-3-yl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-hydroxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-(cyclopentyloxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-hydroxyphenyl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-(cyclopentyloxy)phenyl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-ethoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(7-cyclopropyl-1-propyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

N-(5-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-6(5*H*)-yl)-1-(2-methoxyphenyl)-1*H*-indol-7-yl)cyclopropanecarboxamide;

4-amino-6-(1-isopropyl-7-morpholino-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one; or

N-(5-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-6(5*H*)-yl)-1-isopropyl-1*H*-indol-7-yl)cyclopropanecarboxamide;

or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1 which is:

4-amino-6-(7-cyclopropyl-1-(6-methylpyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-ethylpyrimidin-5-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-chloro-2-methoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-4-methylphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-6-methylpyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxypyrimidin-5-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-ethylphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(5-methylpyrazin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(5-methyl-4*H*-1,2,4-triazol-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-bromo-3-methoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(7-cyclopropyl-1-(5-methylpyrimidin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-2-methylpropyl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;

4-amino-6-(7-cyclopropyl-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one; or

4-amino-6-(7-cyclopropyl-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1-15 and a pharmaceutically acceptable excipient.


17. A method of treating obesity comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to any one of claims 1-15.

18. The compound or pharmaceutically acceptable salt according to any one of claims 1-15 for use in therapy.

19. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-15 for the treatment of obesity.

CLAIMS

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

X is CH, CR^2, or N;

R^1 is $(C_1$-$C_4)$alkyl, $(C_3$-$C_7)$cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, or 5- or 6-membered heteroaryl, wherein said $(C_1$-$C_4)$alkyl is optionally substituted by hydroxyl, $(C_1$-$C_4)$alkoxy, $-CO_2H$, or $-CO_2(C_1$-$C_4)$alkyl, and wherein said phenyl or 5- or 6-membered heteroaryl is optionally substituted by $-O(C_1$-$C_2)$alkylO- or optionally substituted with one to three substituents independently selected from halogen, cyano, oxo, hydroxyl, $(C_1$-$C_4)$alkoxy, halo$(C_1$-$C_4)$alkoxy, $(C_3$-$C_7)$cycloalkoxy, phenyl$(C_1$-$C_2)$alkoxy, $(C_1$-$C_4)$alkyl, halo$(C_1$-$C_4)$alkyl, hydroxy$(C_1$-$C_4)$alkyl, $-CO_2H$, and $-CO_2(C_1$-$C_4)$alkyl; and

R^2 is halogen, $(C_1$-$C_4)$alkyl, halo$(C_1$-$C_4)$alkyl, $(C_3$-$C_7)$cycloalkyl, 4- to 6-membered heterocycloalkyl, $-NHC(O)(C_1$-$C_4)$alkyl, or $-NHC(O)(C_3$-$C_7)$cycloalkyl;

provided that the compound is not 4-amino-6-(1-propyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-cyclopropyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 3-(5-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-6(5*H*)-yl)-1*H*-indol-1-yl)propanoic acid, 4-amino-6-(1-(3-methoxypropyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-methyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-methoxyethyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-isopropyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-propyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-methoxyethyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-cyclohexyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-isopropyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-hydroxyethyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-cyclopropyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-phenyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*]|1,4]oxazepin-5(6*H*)-one, 4-amino-

6-(1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-chlorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-chlorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 6-amino-4-(7-(2-methoxyphenyl)-7*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-3,4-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(2*H*)-one, 4-amino-6-(1-(2-methoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-phenyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3,4-difluorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3,4-difluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(2-fluorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-(trifluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-(trifluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(3-(trifluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(thiazol-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(6-(trifluoromethyl)pyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyridin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyridin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyrazin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(pyrazin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(5-(trifluoromethyl)pyridin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(5-(trifluoromethyl)pyridin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(thiazol-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(6-(trifluoromethyl)pyridin-3-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(6-methylpyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-(difluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, 4-amino-6-(1-(4-(difluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one, or 4-amino-6-(1-(4-(trifluoromethyl)pyridin-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one.

2. The compound or pharmaceutically acceptable salt according to claim 1 wherein X is CH or CR^2.

3. The compound or pharmaceutically acceptable salt according to claim 1 wherein X is CH.

4. The compound or pharmaceutically acceptable salt according to claim 1 or claim 2 wherein R^2 is $(C_3$-$C_7)$cycloalkyl, 4- to 6-membered heterocycloalkyl, or -NHC(O)$(C_3$-$C_7)$cycloalkyl.

5. The compound or pharmaceutically acceptable salt according to claim 4 wherein R^2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, -NHC(O)cyclopropyl, -NHC(O)cyclobutyl, -NHC(O)cyclopentyl, or -NHC(O)cyclohexyl.

6. The compound or pharmaceutically acceptable salt according to any one of claims 1-5 wherein R^1 is $(C_1$-$C_4)$alkyl which is optionally substituted by hydroxyl, $(C_1$-$C_4)$alkoxy, $-CO_2H$, or $-CO_2(C_1$-$C_4)$alkyl.

7. The compound or pharmaceutically acceptable salt according to any one of claims 1-5 wherein R^1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, or tetrahydropyranyl.

8. The compound or pharmaceutically acceptable salt according to any one of claims 1-5 wherein R^1 is phenyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, or triazinyl, each of which is optionally substituted by $-O(C_1$-$C_2)$alkylO- or optionally substituted with one to three substituents independently selected from halogen, cyano, oxo, hydroxyl, $(C_1$-$C_4)$alkoxy, halo$(C_1$-$C_4)$alkoxy, $(C_3$-$C_7)$cycloalkoxy, phenyl$(C_1$-$C_2)$alkoxy, $(C_1$-$C_4)$alkyl, halo$(C_1$-$C_4)$alkyl, hydroxy$(C_1$-$C_4)$alkyl, $-CO_2H$, and $-CO_2(C_1$-$C_4)$alkyl.

9. The compound or pharmaceutically acceptable salt according to claim 8 wherein R^1 is phenyl which is optionally substituted by $-O(C_1$-$C_2)$alkylO- or optionally substituted with one or two substituents independently selected from fluorine, chlorine, hydroxyl, $(C_1$-$C_4)$alkoxy, halo$(C_1$-$C_4)$alkoxy, $(C_3$-$C_7)$cycloalkoxy, $(C_1$-$C_4)$alkyl, and halo$(C_1$-$C_4)$alkyl.

10. The compound or pharmaceutically acceptable salt according to claim 8 wherein R^1 is furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, or isothiazolyl, each of which is optionally substituted with

one or two substituents independently selected from hydroxyl, (C_1-C_4)alkoxy, halo(C_1-C_4)alkoxy, (C_3-C_7)cycloalkoxy, (C_1-C_4)alkyl, and halo(C_1-C_4)alkyl.

11. The compound or pharmaceutically acceptable salt according to claim 8 wherein R^1 is pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl, each of which is optionally substituted with one or two substituents independently selected from oxo, hydroxyl, (C_1-C_4)alkoxy, halo(C_1-C_4)alkoxy, (C_3-C_7)cycloalkoxy, (C_1-C_4)alkyl, and halo(C_1-C_4)alkyl.

12. The compound according to claim 1 which is:

4-amino-6-(1-(oxetan-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-(trifluoromethoxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-cyclobutyl-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-hydroxy-2-methylpropyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-(trifluoromethoxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-4-(trifluoromethyl)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-(difluoromethoxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-isobutoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-isopropoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3,5-dichlorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3,5-dichlorophenyl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2,3-dichlorophenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methylpyrimidin-5-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(6-methylpyridin-3-yl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-hydroxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-(cyclopentyloxy)phenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-hydroxyphenyl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-(cyclopentyloxy)phenyl)-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-ethoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(7-cyclopropyl-1-propyl-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

N-(5-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-6(5*H*)-yl)-1-(2-methoxyphenyl)-1*H*-indol-7-yl)cyclopropanecarboxamide;

4-amino-6-(1-isopropyl-7-morpholino-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

N-(5-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-6(5*H*)-yl)-1-isopropyl-1*H*-indol-7-yl)cyclopropanecarboxamide;

4-amino-6-(7-cyclopropyl-1-(6-methylpyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-ethylpyrimidin-5-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(3-chloro-2-methoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-4-methylphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-6-methylpyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxypyrimidin-5-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-ethylphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(5-methylpyrazin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(5-methyl-4*H*-1,2,4-triazol-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-bromo-3-methoxyphenyl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(7-cyclopropyl-1-(5-methylpyrimidin-2-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;


4-amino-6-(1-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-indol-5-yl)-7,8-dihydropyrimido[5,4-*f*][1,4]oxazepin-5(6*H*)-one;

4-amino-6-(1-(2-methoxy-2-methylpropyl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;

4-amino-6-(7-cyclopropyl-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;

or a pharmaceutically acceptable salt thereof.


13. The compound according to claim 1 which is:



;


or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 which is:



.


15. The compound according to claim 1 which is:



;

or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 1 which is:



;

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1-16 and a pharmaceutically acceptable excipient.

18. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-16 in the manufacture of a medicament for the treatment of obesity.

19. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-16 in the manufacture of a medicament for the treatment of non-alcoholic steatohepatitis.

20. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-16 in the manufacture of a medicament for the treatment of acne.